Tevogen Bio Holdings Inc. (TVGNW) — SEC Filings
Tevogen Bio Holdings Inc. (TVGNW) — 46 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 21 8-K, 6 10-Q, 5 SC 13G/A.
View Tevogen Bio Holdings Inc. on SEC EDGAR
Overview
Tevogen Bio Holdings Inc. (TVGNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Tevogen Bio Holdings Inc. (TVGNW) reported a net loss of $21,597,852 for the nine months ended September 30, 2025, a significant increase from the $4,282,828 net loss in the same period of 2024. This substantial increase in net loss was primarily driven by a decrease in the change in fair value of c
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 3 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Tevogen Bio Holdings Inc. is neutral.
Filing Type Overview
Tevogen Bio Holdings Inc. (TVGNW) has filed 6 10-Q, 21 8-K, 1 DEF 14A, 1 DEFA14A, 1 10-K, 5 SC 13G/A, 5 8-K/A, 2 S-1/A, 3 SC 13G, 1 SC 13D with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of TVGNW's 37 recent filings, 4 were flagged as high-risk, 20 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $ -21,597,852 |
| EPS | $ -0.12 |
| Debt-to-Equity | N/A |
| Cash Position | $ 1,037,094 |
| Operating Margin | N/A |
| Total Assets | $ 4,493,669 |
| Total Debt | $ 12,317,565 |
Key Executives
- Dr. Ryan Saadi
- Ryan H. Saadi
- Boaz R. Weinstein
Industry Context
Tevogen Bio operates in the highly competitive and rapidly evolving clinical-stage immunotherapy sector, focusing on T cell therapies. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory hurdles. Companies in this space often rely on substantial funding rounds and strategic partnerships to advance their pipelines.
Top Tags
biotech (8) · financials (8) · material-agreement (8) · amendment (7) · corporate-action (5) · regulatory-filing (4) · 10-Q (4) · corporate-governance (4) · equity-sale (4) · 8-K (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $21.6M | Increased from $4.3M in 2024 for the nine months ended September 30, 2025, indicating worsening profitability. |
| Cash Balance | $1.04M | Decreased from $1.28M at December 31, 2024, highlighting dwindling liquidity. |
| Total Liabilities | $12.3M | Increased from $10.1M at December 31, 2024, primarily due to a larger loan agreement balance. |
| Research and Development Expenses | $9.0M | Decreased from $28.2M in 2024 for the nine months ended September 30, 2025, potentially signaling a slowdown in core activities. |
| At-the-Market Equity Offering | $50.0M | Potential future funding source, indicating significant dilution risk for existing shareholders. |
| KRHP Grant Commitment | $7.0M | Crucial future funding source, but its receipt is not guaranteed and clinical trials are on hold until funding. |
| Common Stock Shares Outstanding | 198,689,921 | As of November 12, 2025, indicating a large share count subject to further dilution. |
| Par Value Per Share | 0.0001 | Common stock par value |
| Warrant Exercise Price | 11.50 | Price per share for warrant exercise |
| SEC File Number | 001-41002 | Identifies the company's filing history with the SEC |
| IRS Employer Identification No. | 98-1597194 | Tax identification number for the company |
| Reporting Period End Date | 20250331 | Indicates the end of the fiscal quarter covered by the report. |
| Filing Date | 20250514 | The date the 10-Q was officially submitted to the SEC. |
| Fiscal Year End | 2024-12-31 | The period covered by the financial information in the proxy statement. |
| Exercise Price | 11.50 | Warrants exercisable for common stock |
Forward-Looking Statements
- {"claim":"Other institutional investors may re-evaluate their positions in Semper Paratus Acquisition Corp following Polar Asset Management's complete divestment.","entity":"Semper Paratus Acquisition Corp","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tevogen Bio Holdings Inc. (TVGNW)?
Tevogen Bio Holdings Inc. has 46 recent SEC filings from Jan 2024 to Nov 2025, including 21 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TVGNW filings?
Across 46 filings, the sentiment breakdown is: 3 bearish, 42 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Tevogen Bio Holdings Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tevogen Bio Holdings Inc. (TVGNW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tevogen Bio Holdings Inc.?
Key financial highlights from Tevogen Bio Holdings Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TVGNW?
The investment thesis for TVGNW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tevogen Bio Holdings Inc.?
Key executives identified across Tevogen Bio Holdings Inc.'s filings include Dr. Ryan Saadi, Ryan H. Saadi, Boaz R. Weinstein.
What are the main risk factors for Tevogen Bio Holdings Inc. stock?
Of TVGNW's 37 assessed filings, 4 were flagged high-risk, 20 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Tevogen Bio Holdings Inc.?
Recent forward-looking statements from Tevogen Bio Holdings Inc. include guidance on {"claim":"Other institutional investors may re-evaluate their positions in Semper Paratus Acquisition Corp following Pol.